Cargando…

Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial

Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR T) therapy shows remarkable efficacy in patients with relapsed and/or refractory (R/R) multiple myeloma (MM). HBI0101, a novel second generation optimized anti-BCMA CAR T-cell therapy, was developed in an academic setting. W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asherie, Nathalie, Kfir-Erenfeld, Shlomit, Avni, Batia, Assayag, Miri, Dubnikov, Tatyana, Zalcman, Nomi, Lebel, Eyal, Zimran, Eran, Shaulov, Adir, Pick, Marjorie, Cohen, Yael, Avivi, Irit, Cohen, Cyrille, Gatt, Moshe E., Grisariu, Sigal, Stepensky, Polina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Article - Cell Therapy & Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316256/ https://www.ncbi.nlm.nih.gov/pubmed/36200421 http://dx.doi.org/10.3324/haematol.2022.281628

Ejemplares similares

P887: IN-HOUSE ANTI BCMA CAR-T THERAPY FOR THE TREATMENT OF RELAPSED REFRACTORY MULTIPLE MYELOMA: PHASE 1 RESULTS.
por: Asherie, N., et al.
Publicado: (2022)

Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma
por: Harush, Ortal, et al.
Publicado: (2022)

Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?
por: Vainstein, Vladimir, et al.
Publicado: (2023)

miR-103 inhibits proliferation and sensitizes hemopoietic tumor cells for glucocorticoid-induced apoptosis
por: Kfir-Erenfeld, Shlomit, et al.
Publicado: (2016)

A human case of GIMAP6 deficiency: a novel primary immune deficiency
por: Shadur, Bella, et al.
Publicado: (2020)

COVID-19 Among Patients with Hematological Malignancies: Experience from a Tertiary Center Showing Lower Than Expected Mortality and Establishing the Safety of in-Hospital Patient Care during the Pandemic
por: Aumann, Shlomzion, et al.
Publicado: (2021)

Two decades of stem cell transplantation in patients with Fanconi anemia: Analysis of factors affecting transplant outcomes
por: Fink, Orly, et al.
Publicado: (2022)

Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients – a matched control multicenter cohort study
por: Ram, Ron, et al.
Publicado: (2021)

CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival
por: Gross Even-Zohar, Noa, et al.
Publicado: (2022)

Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia
por: Nachmias, Boaz, et al.
Publicado: (2022)

Mesenchymal stroma/stem cells: Haematologists’ friend or foe?
por: Nachmias, Boaz, et al.
Publicado: (2022)

S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

Proteostasis collapse, inter-tissue communication, and the regulation of aging at the organismal level
por: Dubnikov, Tatyana, et al.
Publicado: (2015)

The Emerging Roles of Early Protein Folding Events in the Secretory Pathway in the Development of Neurodegenerative Maladies
por: Dubnikov, Tatyana, et al.
Publicado: (2017)

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
por: Cohen, Adam D., et al.
Publicado: (2023)

Third BNT162b2 mRNA SARS-CoV-2 Vaccine Dose Significantly Enhances Immunogenicity in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
por: Henig, Israel, et al.
Publicado: (2023)

Predictors of death at home among cancer patients in Israel: a population-based study
por: Rottenberg, Yakir, et al.
Publicado: (2021)

Standardization of Molecular MRD Levels in AML Using an Integral Vector Bearing ABL and the Mutation of Interest
por: Nachmias, Boaz, et al.
Publicado: (2023)

A Role for Bcl-2 in Notch1-Dependent Transcription in Thymic Lymphoma Cells
por: Sionov, Ronit Vogt, et al.
Publicado: (2012)

Early integration of palliative care for patients with haematological malignancies
por: Shaulov, Adir, et al.
Publicado: (2022)

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
por: Cho, Shih-Feng, et al.
Publicado: (2018)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
por: Seipel, Katja, et al.
Publicado: (2022)

Utility of Galactomannan Screening for Early Detection of Invasive Aspergillosis in High-Risk Hemato-Oncology Patients
por: Sabbah, Rozan, et al.
Publicado: (2023)

BCMA-targeted immunotherapy for multiple myeloma
por: Yu, Bo, et al.
Publicado: (2020)

Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma
por: Lebel, Eyal, et al.
Publicado: (2022)

Simultaneous Bilateral Femoral Osteonecrosis in Gaucher Disease
por: Cohen, Daniel, et al.
Publicado: (2023)

SUN-033 RNA-Seq Analysis of Ovariectomy-Induced Changes in Mouse Liver Reveals New Targets for Menopause-Associated Metabolic Derangement
por: Stokar, Joshua, et al.
Publicado: (2019)

Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report
por: Li, Dan, et al.
Publicado: (2022)

REGEN‐COV antibody combination in patients with lymphoproliferative malignancies and SARS‐CoV‐2 infection
por: Bronstein, Yotam, et al.
Publicado: (2022)

Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy
por: Cohen, Dan, et al.
Publicado: (2021)

Genomic profiling of bovine corpus luteum maturation
por: Kfir, Sigal, et al.
Publicado: (2018)

Anti-BCMA novel therapies for multiple myeloma
por: Sammartano, Vincenzo, et al.
Publicado: (2023)

Teclistamab impairs detection of BCMA CAR-T cells
por: Glatte, Bettina, et al.
Publicado: (2023)

P966: SMOLDERING MULTIPLE MYELOMA (MM) PROGRESSING TO ACTIVE MM DURING FOLLOW-UP: REDUCED BONE DISEASE AND IMPROVED PROGRESSION-FREE AND OVERALL SURVIVAL COMPARED TO DE-NOVO NEWLY DIAGNOSED MM
por: Fridberg, Gil, et al.
Publicado: (2023)

P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY
por: van de Donk, N., et al.
Publicado: (2023)

Expression of TNF-α, April and BCMA in Behcet's Disease
por: Shaker, Olfat G., et al.
Publicado: (2014)

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
por: Dalla Palma, Benedetta, et al.
Publicado: (2020)

Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation
por: Bera, Tapan K.
Publicado: (2020)

BCMA in Multiple Myeloma—A Promising Key to Therapy
por: Kleber, Martina, et al.
Publicado: (2021)

Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells
por: Reichman, Avinoam, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_87ugnqs1lc48q2l5rue5b0b0c4